Background: In the phase 3 HERO study, the oral GnRH receptor antagonist, relugolix, demonstrated suppression of testosterone to castrate levels in 96.7% of patients, which was superior to leuprolide, and a 54% lower risk of major adverse cardiovascu...
Background: In ccRCC, HIF-2α is involved in the activation of genes such as VEGFA, cyclin D1, and CXCR4, which are associated with angiogenesis, tumor progression, and metastasis. HIF-2α can accumulate and be overactivated due to the inactivation of ...
Background: Gilteritinib is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor that has demonstrated efficacy with favorable tolerability in patients with FLT3-mutated (FLT3mut+) relapsed/refractory acute myeloid leukemia (AML), including internal t...
Background: Mutations in the protein tyrosine phosphatase gene PTPN11 (also known as SHP2) are found in approximately 10% of adult patients with acute myeloid leukemia (AML). A recent study reported that mutated PTPN11 associates with inferior respon...
Background: Person-Centered Oncologic Care and Choices (P-COCC) is a validated ACP paradigm of a values-focused patient (pt) interview augmented by an informational care goals video. In a randomized trial (Epstein et al ASCO 2017), P-COCC was accepta...
Background:The MORPHEUS platform consists of multiple, global, open-label, randomized Phase Ib/II trials designed to identify early efficacy signals and safety of treatment (tx) combinations across cancers. Within MORPHEUS, atezo (anti–PD-L1) was tes...
INTRODUCTION AND OBJECTIVES Low grade upper tract urothelial carcinoma (LG-UTUC) is currently treated by endoscopic resection when possible and by nephroureterctomy (NU) when tumor volume or location preclude conservative management. Endoscopic resec...